Magseed marker delivers 11% cost savings vs guidewires, report finds

A recent study published in the BJS has found that switching to the Magseed marker could significantly reduce costs from increased scheduling flexibility and reduced operating delays.

Pantiora et al (2025) evaluated data from 426 patients, randomised for localisation of the tumour with either a magnetic seed or a guidewire.

The results found that the overall cost per patient reduced by almost €400 with a Magseed marker vs a guidewire, primarily driven by being able to place the seed ahead of the day of surgery, reducing delays to start times and greater localisation success.

This paper follows on from the landmark MagTotal Phase III study, which had previously also demonstrated a reduction in localisation failures (1.9 per cent vs 10.1 per cent for guidewires), shorter operating times and higher staff satisfaction when combining the Magseed marker with the Magtrace lymphatic tracer in a totally magnetic technique.

The key findings:

• The Magseed marker shortened operating times and offered more flexible scheduling and streamlined surgical workflows.
• This led to a reduced total per-patient cost by 11.1 per cent compared to guidewires (€3,123 vs €3,514).
• Robust cost savings persisted across different workflow scenarios.

The report concluded: “Despite higher device costs, magnetic seeds achieved overall cost containment within the frame of a totally magnetic technique through shorter localization and operating times, whilst increasing satisfaction among healthcare practitioners.”

Find out more about Magseed at endomag.com